Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elżbieta Mądro"'
Publikováno v:
The Scientific World Journal, Vol 2012 (2012)
Background and Objectives. The study was conducted to evaluate soft tissue hydration and mass through pattern analysis of vector plots as height, normalized resistance, and reactance measurements by bioelectric impedance vector analysis in Taiwanese
Externí odkaz:
https://doaj.org/article/52b580cc15134726b1ce6b13d82d6172
Autor:
Bożena Winnik, Ewelina Wincza, Krzysztof Brzózka, Ewa Jabłońska, Grzegorz Dubin, Krzysztof Warzocha, Tomasz Sewastianik, Małgorzata Żurawska, Pawel Guzik, Wojciech Czardybon, Izabela Dolata, Ewa Kolasińska, Aleksandra Sabiniarz, Ewa Lech-Marańda, Anna Szumera-Ciećkiewicz, Marta Bugaj, Monika Prochorec-Sobieszek, Elżbieta Mądro, Aniela Golas, Monika Noyszewska-Kania, Ewelina Gabor-Worwa, Renata Windak, Eliza Majewska, Maciej Szydlowski, Magdalena Salwińska, Monika Danielewicz, Bartosz Pula, Milena Mazan, Magdalena Zawadzka, Przemyslaw Juszczynski, Michal Galezowski, Jerome Tamburini
Publikováno v:
Oncotarget
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML). Although FLT3 tyrosine kinase inhibitors initially exhibit clinical activity, resistance to treatmen
Autor:
Paweł Wiechno, Katarzyna Gepner, Aleksandra Czachowska, Elżbieta Mądro, Maciej Krzakowski, Beata Jagielska, Małgorzata Symonides, Konrad Tałasiewicz
Publikováno v:
Nowotwory. Journal of Oncology. 67:34-40
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have inc
Autor:
Janusz Hałka, Elżbieta Iskierka-Jażdżewska, Weronika Piszczek, Krzysztof Warzocha, Marek Hus, Magdalena Piotrowska, Tadeusz Robak, Beata Kumiega, Krzysztof Jamroziak, Elżbieta Mądro, Wanda Knopinska-Posluszny, Jan Maciej Zaucha, Paweł Steckiewicz, Paulina Wieszczy, Krzysztof Giannopoulos, Agnieszka Szeremet, Jadwiga Hołojda, Joanna Drozd-Sokołowska, Marek Dudziński, Marek Osowiecki, Slawomira Kyrcz-Krzemien, Małgorzata Wojciechowska
Publikováno v:
Leukemialymphoma. 58(10)
It is widely understood that outcomes of specific therapy and the burden of adverse events (AEs) found in clinical trials may differ from those seen in routine clinical practice. Several clinical t...
Autor:
Małgorzata Żurawska, Ewa Lech-Marańda, Elżbieta Mądro, Ewa Kolasińska, Bożena Winnik, Krzysztof Brzózka, Tomasz Sewastianik, Jerome Tamburini, Ewelina Gabor-Worwa, Ewa Jabłońska, Bartosz Pula, Izabela Dolata, Monika Danielewicz, Pawel Guzik, Anna Szumera-Ciećkiewicz, Ewelina Wincza, Aleksandra Sabiniarz, Krzysztof Warzocha, Wojciech Czardybon, Magdalena Salwińska, Monika Prochorec-Sobieszek, Maciej Szydlowski, Renata Windak, Aniela Golas, Grzegorz Dubin, Marta Bugaj, Magdalena Zawadzka, Przemyslaw Juszczynski, Michal Galezowski
Publikováno v:
Cancer Research. 77:4087-4087
Despite huge effort spent on understanding the pathogenesis of acute myeloid leukemia (AML), current standards of care are still based on the same chemotherapy agents as two decades ago - combinational treatment of cytarabine with an anthracycline. F
Autor:
Krzysztof Brzózka, Ewelina Gabor-Worwa, Pawel Guzik, Magdalena Zawadzka, Przemyslaw Juszczynski, Anna Szumera-Ciećkiewicz, Elżbieta Mądro, Tomasz Sewastianik, Bożena Winnik, Monika Prochorec-Sobieszek, Michal Galezowski, Krzysztof Warzocha, Aniela Golas, Renata Windak, Wojciech Czardybon, Ewa Lech-Marańda
Publikováno v:
Acta Haematologica Polonica. 46:28
Autor:
Maciej Szydlowski, Elżbieta Mądro, Agnieszka Przybylowicz, Ewelina Gabor-Worwa, Bożena Winnik, Wojciech Czardybon, Tomasz Sewastianik, Krzysztof Warzocha, Ewa Lech-Marańda, Emilia Bialopiotrowicz, Krzysztof Brzózka, Aniela Golas, Renata Windak, Przemyslaw Juszczynski, Michal Galezowski
Publikováno v:
Cancer Research. 75:5394-5394
Despite huge effort spent on understanding acute myeloid leukemia (AML), current standards of care are still based on the same chemotherapy agents as two decades ago - typically based on cytarabine chemotherapy with an anthracycline. Although patient
Autor:
Krzysztof Brzózka, Ewa Lech-Marańda, Tomasz Sewastianik, Emilia Bialopiotrowicz, Elżbieta Mądro, Izabela Dolata, Katarzyna Borg, Przemyslaw Juszczynski, Bożena Katarzyna Budziszewska, Magdalena Salwińska, Renata Windak, Maciej Szydlowski, Wojciech Czardybon
Publikováno v:
Cancer Research. 74:1749-1749
PIM kinases represent an emerging therapeutic target in multiple hematological malignancies, as exemplified by currently ongoing phase I clinical trials by Astra Zeneca (AZD1208) and Novartis (LGH447) in acute myeloid leukemia and multiple myeloma. S